# Okami Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/okami-medical

- Industry: Medical Devices & Equipment
- Headquarters: Aliso Viejo, US
- Website: www.okamimedical.com/
- Total disclosed funding: $55M
- Latest round: Series F (Nov 18, 2025)
- Investors on record: 3

## About

Okami Medical, Inc. is a US-based company specializing in innovative vascular occlusion technologies, providing advanced solutions for healthcare providers to effectively manage blood flow in peripheral vascular interventions.Founded in 2017 in Aliso Viejo, California, Okami Medical, Inc. develops and markets cutting-edge vascular occlusion devices. Okami Medical specializes in innovative vascular occlusion technologies, prominently featuring the LOBO HD BRAID Vascular Occluder and accompanying delivery systems like the SENDERO Microcatheter and SENDERO MAX Delivery Catheter. The LOBO device is designed to achieve rapid and effective occlusion—averaging just 90 seconds—allowing for a swift solution in various peripheral vascular cases. It distinguishes itself from traditional vascular plugs and coils through its unique high-density, small-pore HD BRAID technology, which enhances performance and reliability. The primary clientele includes healthcare providers and facilities that perform vascular interventions, with the products being utilized in the peripheral vasculature of patients requiring therapeutic or diagnostic blood flow obstruction. Okami Medical's offerings are marketed primarily in the United States, addressing the needs of hospitals, interventional radiologists, and vascular surgeons.Okami Medical generates revenue through the sale of its medical devices directly to healthcare providers and institutions. The transaction structure consists of B2B sales, where hospitals and clinics order devices based on patient needs and procedural requirements. The LOBO HD BRAID Vascular Occluder, along with the SENDERO delivery systems, forms the core of their product portfolio, facilitating essential vascular procedures. Each transaction typically occurs through direct orders placed by physicians or procurement departments, with pricing reflective of the specialized nature of the devices. These sales are subject to regulatory approval and are limited to transactions with licensed medical professionals, ensuring compliance with federal regulations. In November 2025, Okami Medical, Inc. raised USD 45 million in venture funding led by Gilde Healthcare, with participation from US Venture Partners and Vensana Capital. Other unspecified investors also participated in the round. The company plans to utilize the November 2025 funding to expand commercial footprint and advance clinical programs for vascular embolization solutions and support continued development of devices for occlusion of peripheral vessels.

## Funding rounds

- Series F, Nov 18, 2025, $29M — US Venture Partners, Gilde Healthcare, Vensana Capital
- Series F, Aug 30, 2024, $19M — US Venture Partners, Vensana Capital
- Series D, Jun 5, 2020, $7.2M — US Venture Partners

## Investors

- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series D, Series F
- Vensana Capital (https://capitalatlas.ai/funds/vensana-capital) — Series F
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series F